Started 3 weeks, 5 days ago (2009-10-15 05:58:00)
by gdpawel
A study was presented at the symposium about progress in drug selection through the use of cell-based functional profiling. It delt with the so-called "triple negative" breast cancer (TNBC), which is estrogen receptor negative (ER-), progesterone receptor negative (RP-), and Her2 negative (H2-).
When breast cancer presents as locally advanced disease, it is customarily treated with ...
Thread:
Show this thread (4 posts)
Size: 4,524 bytes
Related Threads: Same Site | All Sites
Customize:
Related Threads: Same Site | All Sites
Customize:

